Abstract: The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Abstract: A system that verifies that a hunter has complied with the conditions of a hunting tag by requiring the hunter to submit a sample (such as a blood sample) of the killed animal with a harvest report; the sample is analyzed to develop a profile of the animal killed, which is then compared to the authorized kills associated with the hunting tag. Sample analysis may determine for example the species, subspecies, or other category of the animal, its sex, its approximate age, the development of body parts such as antlers, and when the animal was killed. Comparison of this data to hunting tag restrictions may be fully or partially automated, enabling efficient flagging of potential violations. Sample analysis may generate a DNA fingerprint that may be used later to cross-check against other animal samples, for example to check trophies or meat to see if they come from verified legal hunts.

Abstract: A reloadable magazine apparatus that accepts two or more cartridges that enables users to quickly load a plurality of cartridges into the magazine through a loading window, for use in a firearm. Embodiments of the invention enable a user to place a clip of cartridges directly in the magazine, for example a stripper clip, and rapidly load the magazine. Embodiments of the invention enable the magazine to be configured for use in capacity and removable magazine restricted states through the incorporation of ammunition stops and locking tabs.

Abstract: The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Abstract: The present disclosure describes PD-L1 gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Abstract: The present disclosure describes gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Abstract: The present disclosure describes IFN-? gene signature biomarkers that are useful for identifying cancer patients who are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods and kits for testing tumor samples for the biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Abstract: The present invention provides, inter alia, methods for treating tumors that are sensitive to an IGF1R inhibitor. The tumor are determined to be sensitive if the level of IGF1 mRNA expression in the tumor cells, relative to one or more reference genes, reaches a certain threshold level. Methods for evaluating patients as candidates for receipt of the IGF1R inhibitor therapy are also provided as well along with in vitro assay methods and kits for performing any of the methods.

Abstract: The present invention may be used in systems for non-volatile memory storage of electronic data. A first substrate member may have a first and second surface with a first and second substrate connector spaced apart and attached to the first surface and a first and second spacer element spaced apart and attached to said second surface. A NAND flash controller device may be mounted on the first surface and connected to the substrate connectors and spacer elements. Multiple NAND memory devices may be mounted on the second surface and be connected to the NAND flash controller device. A second substrate member may have a first and second surface with multiple NAND flash memory devices mounted on at least one of the surfaces. The second substrate member may be attached to the spacer elements on the first surface and said multiple NAND flash memory devices may be connected to the NAND flash controller device.

Abstract: A continuous throttle regulation device employs a motor throttle body located proximate to a motor or engine, and an accelerator pedal located remote from the motor or engine. A return switch (RS) is responsive to the motor throttle body, and a pressure sensitive switch (PSS) is responsive to the accelerator pedal position. Power is passed through both switches then to a critical electronic element required to run the motor, such as a distributor. Therefore, when both switches are open, power to the critical element is interrupted, slowing or stopping the motor. When both switches are closed, the power is restored to the ignition causing the motor to operate. Therefore, the system may engage and disengage automatically and intermittently numerous times in a short period of time, thereby safely limiting motor speed, while restoring power in a split second to keep the motor running and operational. This technology may also be applied to gasoline, diesel, and electric motors to regulate their operation.

Abstract: A continuous throttle regulation device employs a motor throttle body located proximate to a motor or engine, and an accelerator pedal located remote from the motor or engine. A return switch (RS) is responsive to the motor throttle body, and a pressure sensitive switch (PSS) is responsive to the accelerator pedal position. Power is passed through both switches then to a critical electronic element required to run the motor, such as a distributor. Therefore, when both switches are open, power to the critical element is interrupted, slowing or stopping the motor. When both switches are closed, the power is restored to the ignition causing the motor to operate. Therefore, the system may engage and disengage automatically and intermittently numerous times in a short period of time, thereby safely limiting motor speed, while restoring power in a split second to keep the motor running and operational. This technology may also be applied to gasoline, diesel, and electric motors to regulate their operation.

Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.

Abstract: The present invention provides the identification of genes that are expressed in tumors that are responsive to a given therapeutic agent and whose expression (either increased expression or decreased expression) correlates with responsiveness to that therapeutic agent. One or more of the genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by that agent.